Prof Mekhail speaks with ecancer at NOSCM 2017 targeted therapies for lung cancer. He looks beyond EGFR and ALK mutations to emerging targets in lung cancer including BRAF and HER2, which have significant histories in other disease but are now...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vJeA3V
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic l...
-
About 540 million years ago a group of jellyfish washed ashore, died and fossilised – preserving evidence of the earliest example of an anim...
-
The pursuit for clarity in diagnostic and treatment pathways for the complex, chronic condition of myalgic encephalomyelitis/chronic fatigue...
-
Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only too...
-
Abstract Objective To study clinical profile and outcome in patients with methemoglobinemia following exposure to toxic colors during Ho...
-
<span class="paragraphSection"><div class="boxTitle">Background</div>In Australia, high uptake of the ...
-
Facial Nerve Clinic to Provide Comprehensive Personalized Care Newswise (press release) The program will treat patients with facial n...
-
Sarcoidosis is a multisystem granulomatous syndrome of unknown etiology with noncaseating epithelioid granulomas being the pathognomonic pat...
-
Acquired Vascular Tumors of the Head and Neck. Otolaryngol Clin North Am. 2017 Oct 26;: Authors: Persky M, Tran T Abstract Vascular...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου